Olive oil, an important component of the Mediterranean diet, produces cardioprotective effects, probably due to both oleic acid and the polyphenols such as oleuropein and hydroxytyrosol. Our aim in this study was to assess whether a polyphenol-enriched extract from the leaves of Olea europaea L. with oleuropein as the major component attenuated the cardiovascular, hepatic, and metabolic signs of a high-carbohydrate, high-fat (HCHF) diet (carbohydrate, 52%; fat, 24%, 25% fructose in drinking water) in rats. Male Wistar rats were fed either a cornstarch diet (CS) or a HCHF diet for a total of 16 wk. Diets of the treatment groups [CS+olive leaf extract (OLE) and HCHF+OLE] were supplemented with 3% OLE after 8 wk of being fed their respective CS or HCHF diets for a further 8 wk. After 16 wk, HCHF rats developed signs of metabolic syndrome, including elevated abdominal and hepatic fat deposition, collagen deposition in heart and liver, cardiac stiffness, and oxidative stress markers (plasma malondialdehyde and uric acid concentrations), with diminished aortic ring reactivity, abnormal plasma lipid profile, impaired glucose tolerance, and hypertension. Compared with HCHF rats, those in the HCHF+OLE group had improved or normalized cardiovascular, hepatic, and metabolic signs with the exception of elevated blood pressure. These results strongly suggest that an OLE containing polyphenols such as oleuropein and hydroxytyrosol reverses the chronic inflammation and oxidative stress that induces the cardiovascular, hepatic, and metabolic symptoms in this rat model of diet-induced obesity and diabetes without changing blood pressure. J. Nutr. 140: 946-953, 2010. 
Introduction
The Mediterranean diet has been credited with many beneficial effects in the prevention and treatment of cardiovascular diseases (1) , including improvement of lipid profiles, reduction in blood pressure, insulin resistance, blood glucose concentrations, inflammatory biomarkers, and total mortality (2) . The cardioprotective effects of olive oil, one of the important components of the Mediterranean diet, have been attributed to oleic acid, the major fatty acid in the oil, as well as the polyphenols, hydroxytyrosol and oleuropein (3, 4) .
Olive leaves present a unique opportunity to study the effects of olive oil polyphenols on metabolic profile and cardiovascular and hepatic structure and function, because the leaf contains these polyphenols with only a small amount of oleic acid. Methanolic extracts of olive leaves contain secoiridoids such as oleuropein, ligostroside, dimethyloleuropein, and oleoside (5); flavonoids, including apigenin, kaempferol, and luteolin; as well as phenolic compounds such as caffeic acid, tyrosol, and hydroxytyrosol (6) . Oleuropein, the major phytochemical in olive leaf, is a complex phenol present in large quantities in olive leaves but in lower quantities in olive oil (7) . Oleuropein can be hydrolyzed to hydroxytyrosol, elenolic acid, oleuropein aglycone, and glucose (8, 9) .
In vitro, oleuropein and its major metabolite, hydroxytyrosol, exhibited a range of pharmacological properties beneficial for the cardiovascular system. These actions included inhibition of the proliferation of McCoy cells derived from the synovial fluid in the knee joint (10) , enhanced nitric oxide production by mouse macrophages (11) , antiinflammatory effects (12) , protection against oxidative myocardial injury induced by ischemia and reperfusion (9) , decreased blood pressure, inhibition of platelet aggregation and eicosanoid production, and scavenging of free radicals in addition to inhibition of 5-and 12-lipoxygenases (13) . Oleuropein reduced infarct size, plasma lipid concentrations, and plasma markers of oxidative stress in cholesterol-fed rabbits (14, 15) .
In vivo, olive leaf extract (OLE) 6 lowered blood cholesterol (16) and lipid (17) concentrations in cholesterol-fed rats and lowered blood pressure in nitro-L-arginine methyl ester-induced hypertensive rats (18) as well as in normotensive rats (19) . In streptozotocin-induced diabetic rats, OLE decreased serum concentrations of glucose, lipids, uric acid, creatinine, and liver enzymes (20) .
In this study, we determined the effects of OLE in a highcarbohydrate, high-fat (HCHF) diet-induced model of the metabolic syndrome in rats. In particular, we measured cardiovascular responses such as blood pressure, cardiac collagen deposition and stiffness, metabolic responses such as glucose tolerance and abdominal fat deposition, as well as changes in liver structure and function.
Materials and Methods
OLE preparation and analysis. Freshly harvested olive leaves (4 kg) were extracted for 2 wk with 16 L of ethanol at room temperature. The biomass was removed and 8000 mL of the extract was reduced to 835 mL in a rotary evaporator; this concentrated extract is referred to as OLE. Assays of OLE including oleuropein and hydroxytyrosol concentrations were performed at the Centre for Phytochemistry and Pharmacology, Southern Cross University, Australia. The chemical profile of OLE was obtained using an Agilent HPLC (series 1100) equipped with a diode array detector and coupled to an Agilent mass selective detector (series 1100) operating in atmospheric pressure chemical ionization mode. The extract was dissolved in 100% analytical reagent grade methanol and filtered through a Whatman polytetrafluoroethylene membrane filter (0.45 mm) prior to loading the sample (10 mL injection volume). Chromatographic separations were carried out on a Phenomenex Aqua C18 column (5 mm: 150 3 4.6 mm i.d.) using ultra pure water and acetonitrile (LAB-SCAN, code C2502U) as the mobile phases at a flow rate of 1 mL/min. Positive fragmentor voltage was set at 150 volts and absorbance was monitored between 230 and 280 nm. All solvents were HPLC grade and contained 0.005% trifluoroacetic acid (Sigma-Aldrich Australia) to enhance peak shape. Oleuropein and hydroxytyrosol were quantified using commercial standards (Sigma-Aldrich Australia).
Rats and diets. Male Wistar rats (8-9 wk old, 318 6 3 g, n = 50) were supplied by The University of Queensland Biological Resources unit and were individually caged at the School of Biomedical Sciences Animal House Facility. All experimentation was approved by the Animal Experimentation Ethics Committee of The University of Queensland under the guidelines of the National Health and Medical Research Council of Australia. All experimental groups were housed in a temperature-controlled, 12-h-light/-dark cycle environment with ad libitum access to water and the group-specific rat diet. Daily body weight, food, and water measurements were taken to monitor the dayto-day health of the rats.
The rats were randomly divided into 4 separate groups: cornstarch (CS; n = 10), CS+OLE (n = 10), HCHF (n = 20), and HCHF+OLE (n = 10). CS and HCHF rats were fed their respective diets throughout the 16-wk protocol ( Table 1) . Ten rats were killed from the HCHF group at 8 wk to assess the pathophysiological state prior to OLE intervention. CS +OLE and HCHF+OLE rats were fed a normal CS or HCHF diet for the first 8 wk of the protocol after which their respective diets were supplemented with 3% OLE replacing an equivalent volume of water (Table 1) .
All group-specific diets were custom prepared in our laboratory. The CS diet was prepared by thoroughly mixing cornstarch, powdered rat feed (meat-free rat and mouse feed, Specialty Feeds), Hubble, Mendel and Wakeman salt mixture (21) (MP Biochemicals), and water while the cornstarch and part of the water were replaced with condensed milk, fructose, and beef tallow in the HCHF diet ( Table 1) . The drinking water for the HCHF and HCHF+OLE groups was augmented with 25% fructose for the entire 16 wk. OLE-supplemented diets were prepared by replacing an equivalent amount of water in the diet with the extract (Table 1) . Energy intakes for the respective groups were calculated from the following values (kJ/g): fructose, 15.4; cornstarch, 15.9; condensed milk, 13.9; beef tallow, 37.7; and powdered rat feed, 14.0. For the HCHF and HCHF+OLE groups, energy from their 25% fructosesupplemented drinking water was also considered for calculating their energy intake.
Systolic blood pressure was measured in rats after 0, 4, 8, 12, and 16 wk of dietary intervention under light sedation with intraperitoneal (i.p.) Zoletil (toletamine, 15 mg/kg and zolazepam, 15 mg/kg i.p.; Virbac). Measurements were taken using an MLT1010 Piezo-Electric Pulse Transducer (ADInstruments) and an inflatable tail-cuff connected to a MLT844 Physiological Pressure Transducer (ADInstruments) and PowerLab data acquisition unit (ADInstruments). Abdominal circumference was determined using a standard measuring tape after every blood pressure measurement.
Basal blood glucose concentrations were measured in tail vein blood using a Medisense Precision Q.I.D glucose meter (Abbott Laboratories) after overnight (10-12 h) food deprivation. Fructose-supplemented drinking water in the HCHF and HCHF+OLE groups was replaced with normal water for the overnight food-deprivation period for the measurement of basal blood glucose concentrations. The rats were given 2 g/kg body weight of glucose as a 40% solution via oral gavage. Tail vein blood samples were taken at 0, 30, 60, 90, and 120 min following glucose administration.
Echocardiography. Echocardiographic examination (Phillips iE33, 12
MHz transducer) was performed at 8 and 16 wk as previously described A short axis view of the left ventricle (LV) at the level of the papillary muscles was obtained and used for direct acquisition of M-mode images of the LV for measurement of diastolic anterior wall thickness, diastolic posterior wall thickness, left ventricular internal systolic dimension, and left ventricular end-diastolic dimension. Measurements were taken in accordance with the guidelines of the American Society of Echocardiography using the leading-edge method (23) . For these variables, diastole was defined by the beginning of the QRS complex on the simultaneously recorded electrocardiogram and systole identified as the nadir of systolic anterior wall motion independent of the electrocardiogram complex.
Pulsed-wave Doppler velocity profiles of mitral inflow was obtained from the left apical 4-chamber view for measurement of early and late mitral inflow velocity and early mitral inflow velocity:late mitral inflow velocity (E:A) ratios, mitral inflow E-wave deceleration time, and time from mitral valve closure to opening (MCMO). A pulsed-wave Doppler velocity profile of the ascending aorta was obtained from a suprasternal view for measurement of aortic velocity, ejection time, and the diameter of the ascending aorta at the point of transition to the transverse aorta.
Derived indices of left ventricular systolic function [fractional shortening (FS%), ejection fraction (EF%)] were calculated using wellestablished formulae (22) . Left ventricular mass was estimated using the standard cube equation subsequently modified by Litwin et al. (24):
] 3 0.8 + 0.14, where 1.04 is the specific gravity of muscle, IVSDd is interventricular septum diameter in diastole (cm), LVIDd is left ventricular internal diameter in diastole (cm), and LVPWd is left ventricular posterior wall thickness in diastole (cm). The multiplication factor of 0.8 and the addition factor of 0.14 are constants (dimensionless) similar to that used in the anatomically validated Devereux correction for the American Society for Echocardiography dimensions in humans, which allows more accurate prediction of LV mass in rats (24) .
Isolated Langendorff heart. The left ventricular function of the rats in all treatment groups was assessed using the Langendorff heart preparation. Terminal anesthesia was induced via i.p. injection of pentobarbitone sodium (Lethabarb, 100 mg/kg). Blood (;5 mL) was immediately drawn out of the abdominal aorta after heparin (Sigma-Aldrich Australia) administration (1000 IU) through the right femoral vein. Isovolumetric ventricular function was measured by inserting a latex balloon catheter into the LV connected to a Capto SP844 MLT844 physiological pressure transducer and Chart software on a Maclab system (ADInstruments Australia and Pacific Islands). All left ventricular end-diastolic pressure values were measured while pacing the heart at 250 beats/min using an electrical stimulator. End-diastolic pressures were obtained starting from 0 mm Hg up to 30 mm Hg. The diastolic stiffness constant (k, dimensionless) was calculated as in previous studies (25) .
Organ bath studies. Thoracic aortic rings (4 mm in length) were suspended in an organ bath chamber with a resting tension of 10 mN. Cumulative concentration-response (contraction) curves were measured for noradrenaline (Sigma-Aldrich Australia) and concentration-response (relaxation) curves were measured for acetylcholine (Sigma-Aldrich Australia) and sodium nitroprusside (Sigma-Aldrich Australia) in the presence of a submaximal (70%) contraction to noradrenaline (25) .
Organ weights. The right ventricle (RV) and LV were separated after perfusion experiments and weighed. Liver and abdominal fat were immediately removed at the time of the heart removals for perfusion experiments and blotted dry for weighing. Perirenal, epididymal, and omental fat were together weighed as abdominal fat. Organ weights were normalized relative to the tibial length at the time of their removal (in mg/mm).
Histology. Immediately after removal, heart and liver tissues were fixed in 10% buffered formalin for 3 d with a change of formalin solution every day to remove traces of blood from the tissue. The samples were then dehydrated and embedded in paraffin wax. Thin sections (10 mm) of the LV and liver were cut and stained with hematoxylin and eosin stain for determination of inflammatory cell infiltration. Liver sections were also stained with Milligan's Trichrome stain to determine fibrosis. Collagen distribution was measured in the LV with picrosirius red stain and analyzed by laser confocal microscopy (Zeiss LSM 510 upright Confocal Microscope) (25) . Color intensity was quantitatively analyzed using NIH-ImageJ software (NIH) to determine the extent of collagen deposition in selected tissue sections. Plasma analysis. Briefly, blood was centrifuged at 5000 3 g for 15 min within 30 min after collection into heparinized tubes. Plasma samples were separated and transferred in Eppendorf tubes for analysis. Plasma enzymatic activities and analyte concentrations were determined using kits and controls supplied by Olympus 7 using an Olympus analyzer (AU 400). Nonesterified fatty acids were quantitatively determined using HR Series NEFA-HR 2 kit (Wako). Plasma malondialdehyde concentrations were measured by HPLC (Shimadzu) as previously described (26) . Plasma antioxidant capacity was measured based on the inhibition of the absorbance of the radical cation of 2,29-azinobis(3-ethylbenzothiazoline 6-sulfonate) by 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid equivalent antioxidants using a Cobas-Mira automated analyzer as previously described (27) .
Statistical analysis. All data are presented as mean 6 SEM. Results were tested for variance using Bartlett's test and variables that were not normally distributed were transformed (using log 10 function) prior to statistical analyses. Data from the CS, CS+OLE, HCHF, and HCHF +OLE groups were tested by 2-way ANOVA. When interaction and/or the main effects were significant, means were compared using NewmanKeuls multiple comparison post test. Where transformations did not result in normality or constant variance (total plasma cholesterol, plasma nonesterified fatty acids (NEFA), lactate dehydrogenase (LDH), malondialdehyde, and urea concentrations, and food intake), a Kruskal-Wallis nonparametric test was performed. Data from the HCHF 8 wk and HCHF 16 wk groups as well as mean oleuropein/hydroxytyrosol intakes by the CS+OLE and HCHF+OLE groups were compared using Student's t test. P , 0.05 was considered significant. All statistical analyses were performed using GraphPad Prism version 5.00 for Windows.
Results
Chemical profile of OLE. Eight peaks corresponding to oleoside, hydroxytyrosol, tyrosol, aesculin, hydroxypinoresinol-glycoside, luteolin glucoside derivative, oleuropein, and luteolin 7-glucoside were identified in the extract using MS and UV spectra (Supplemental Fig. 1 ). Verbascoside, elenolic acid, and apigenin derivatives could not be conclusively detected. The concentrations of the major component, oleuropein (13.04 g/L) and its major metabolite, hydroxytyrosol (2.73 g/L), were determined.
Dietary intake and body weights. Food intake was reduced in the HCHF and HCHF+OLE rats compared with the CS and CS +OLE groups ( Table 2) . However, OLE supplementation by itself did not affect mean food intake in either group but increased water consumption in the CS+OLE rats (Table 2 ). Due to the reduced food intake, mean daily intakes of oleuropein and hydroxytyrosol in HCHF+OLE rats were lower (20.7 6 0.3 mg/ kg and 4.3 6 0.1 mg/kg body weight, respectively) than in CS +OLE rats (31 6 1 mg/kg and 6.5 6 0.2 mg/kg body weight, respectively). Energy intake was higher in HCHF rats and this was associated with a greater final body weight and larger Olive leaf polyphenols in the metabolic syndrome 949
abdominal fat pads compared with CS rats (Table 2) . Although OLE supplementation did not alter the energy intake in any group, it selectively reduced body weight in the CS+OLE rats but not in the HCHF+OLE rats (Table 2 ).
Metabolic and oxidative stress. HCHF rats had a near doubling of abdominal fat deposition and almost 25% greater abdominal circumference compared with the CS rats after 16 wk. OLE supplementation prevented the increase in the abdominal fat pads and attenuated the increase in the abdominal circumference in both the CS+OLE and HCHF+OLE groups ( Table 2) . Basal blood glucose, plasma total cholesterol, triglyceride, and NEFA concentrations were elevated in HCHF rats compared with the CS group ( Table 3) . In addition to the lower plasma total cholesterol and triglyceride concentrations, the HCHF+OLE group had improved oral glucose tolerance at 16 wk (Table 3) . OLE supplementation did not affect plasma NEFA concentrations in any group or other plasma lipids in CS+OLE rats (Table 3) . Although the basal blood glucose level was elevated in CS+OLE rats, they nevertheless had comparable glucose tolerance to CS rats ( Table 3) . The blood glucose concentrations in the HCHF rats remained elevated 120 min after glucose loading compared with the CS-and OLEsupplemented rats (Table 3) .
HCHF rats had greater LDH activity and lower plasma urea concentrations at both 8 and 16 wk compared with the CS group. OLE supplementation attenuated these changes by reducing LDH activity and restoring the decreased nitrogen metabolism indicated by higher urea concentrations in HCHF +OLE rats (Table 3) . Compared with CS rats, the CS+OLE group had elevated plasma LDH activity and reduced urea concentration ( Table 3) .
The HCHF rats also had higher concentrations of plasma oxidative stress markers with elevated plasma malondialdehyde and uric acid concentrations compared with CS rats. Plasma from the HCHF group also had a lowered capacity to neutralize free radicals as shown by the total antioxidant capacity (Table  3) . On the contrary, the HCHF+OLE rats had lower concentrations of the measured markers of oxidative stress compared with HCHF rats (Table 3) . OLE supplementation reduced the plasma malondialdehyde, but not uric acid, concentrations in CS+OLE rats compared with the CS group (Table 3) . OLE supplementation did not alter the plasma total antioxidant capacity in either the CS+OLE or HCHF+OLE rats compared with the CS and HCHF groups, respectively (Table 3 ).
Cardiovascular changes. HCHF feeding also changed cardiovascular structure and function. Systolic blood pressure increased in the HCHF group compared with the CS group. OLE supplementation did not affect systolic blood pressure at 16 wk (Table 3) .
Noninvasive echocardiographic assessment of HCHF rats showed larger LVIDd, reduced FS and EF, greater relative wall thickness, higher estimated LV mass, reduced E:A ratio, and decreased MCMO duration compared with CS group (Table 3) . Compared with HCHF rats, HCHF+OLE rats had smaller LVIDd and reduced estimated LV mass. OLE supplementation did not affect relative wall thickness, E:A, ratio, or MCMO duration in HCHF+OLE rats or any parameter in CS+OLE rats assessed by echocardiography (Table 3) . FS, EF, and deceleration time remained unaffected by diet or treatment (Table 3) .
Ex vivo cardiac function as measured in the Langendorff isolated heart showed a markedly higher cardiac stiffness in the HCHF rats compared with the CS group (Table 3) . OLE supplementation reversed the increased cardiac stiffness in HCHF+OLE rats (Table 3 ). HCHF rats also had increased LV wet weight compared with the CS and HCHF+OLE groups (Table 3) . Neither diet nor treatment affected the RV wet weight (Table 3) .
Furthermore, HCHF feeding diminished vascular responses in isolated thoracic aortic rings to noradrenaline, sodium nitroprusside, and acetylcholine compared with CS rats (Fig.  1A-C) . In the HCHF+OLE group, OLE supplementation prevented any further decrease in vasorelaxation induced by sodium nitroprusside and acetylcholine (Fig. 1B,C ) compared with HCHF rats at 8 wk but failed to attenuate the decreased contractility to noradrenaline (Fig. 1A) . Vascular responses in isolated thoracic aortic rings from the CS+OLE rats remained unchanged compared with the CS rats (Fig. 1A-C) .
After 16 wk, HCHF rats had greater infiltration by inflammatory cells into the LV (Fig. 2D) as well as increased interstitial collagen deposition ( Fig. 2I ; Table 3 ) compared with CS rats ( Fig. 2A,F ; Table 3 ). OLE-treated HCHF rats had a normalized inflammatory state (Fig. 2E ) and markedly reduced collagen deposition ( Fig. 2J; Table 3 ), but OLE treatment did not change inflammatory cell infiltration or collagen deposition in CS rats ( Fig. 2B,G ; Table 3 ).
Hepatic structure and function. Although liver weight did not differ between CS and HCHF rats, plasma markers of liver function were elevated in HCHF rats as early as 8 wk and further increased at 16 wk compared with CS rats (Table 3) . OLEsupplemented rats had lower liver wet weight compared with CS and HCHF rats in addition to normalized plasma markers of liver function so that values were similar to those in CS rats ( Table 3) .
The CS (Fig. 3A,F ,K) and CS+OLE (Fig. 3B ,G,L) groups had negligible lipid accumulation, inflammatory cell infiltration, and fibrosis. Minor changes were observed at 8 wk with HCHF feeding (Fig. 3C,H,M) . HCHF feeding for 16 wk increased the size of the fat vacuoles within the hepatocytes (Fig. 3D) with increased portal inflammatory cell infiltration (Fig. 3I ) and portal fibrosis ( Fig. 3N ; Table 3 ). The OLE supplemented rats displayed normalized macrovesicular steatosis (Fig. 3E) , portal inflammation (Fig. 3J) , and fibrosis ( Fig. 3O; Table 3 ).
Discussion
In this study, young male Wistar rats fed a HCHF diet were used as an experimental model of metabolic syndrome. The HCHF diet produced changes in metabolic variables as well as in Olive leaf polyphenols in the metabolic syndrome 951 cardiovascular and liver structure and function. OLE supplementation improved glucose tolerance and normalized abdominal fat deposition as well as plasma triglyceride and total cholesterol concentrations. Such effects were accompanied by reduced plasma uric acid and malondialdehyde concentrations, therefore suggesting a decrease in oxidative stress. Furthermore, histological evaluation of heart and liver showed reduced inflammation and fibrosis. This was accompanied by reduced LV stiffness, reduced portal inflammation and fat deposition in the liver, and total restoration of liver function as well as improved aortic reactivity. OLE supplementation did not reduce blood pressure in our diet-induced model of metabolic syndrome, in contrast to the hypotensive effect of olive leaves reported in nitro-L-arginine methyl ester-induced hypertensive rats (18) and anesthetized normotensive rats (19) with the extract doses of 100 mg/(kg×d) and 180 mg/kg as a single dose, respectively, compared with the 2.6 6 0.04 mL/(kg×d) extract dose in our experiments.
These responses to olive leaf supplementation are consistent with reported pharmacological responses to both oleuropein and its principle colonic metabolite, hydroxytyrosol. The responses likely to lead to cardioprotection include antiinflammatory effects (7-9), protection against oxidative myocardial injury induced by ischemia and reperfusion (9) , inhibition of platelet aggregation and eicosanoid production, and scavenging of free radicals in addition to inhibition of 5-and 12-lipoxygenases (13), as well as reduced infarct size and plasma markers of oxidative stress (14, 15) . In vivo, hydroxytyrosol lowered blood cholesterol (16) and lipid (17) concentrations in cholesterol-fed rats at doses ranging from 2.5 to 5 mg/kg, while in streptozotocin-induced diabetic rats, OLE (100-500 mg/kg) decreased serum concentrations of glucose, lipids, uric acid, creatinine, and liver enzymes (20) . The decreased blood lipid concentrations could be due to agonist actions on bile acidactivated TGR5, a metabotropic G-protein-coupled receptor (28) . Bile acids increase energy expenditure by a TGR5-mediated increase in intracellular activation of thyroid hormone, hence preventing the development of obesity and insulin resistance in mice fed a high-fat diet (29) . Luteolin, another major component of olive leaves, and its derivatives inhibited superoxide anion-mediated impairment of endothelium (30, 31) , improved endothelium-dependent relaxation in rat aorta (31) , inhibited angiotensin-converting enzyme (32) and nuclear factor k light chain enhancer of activated B cell activation, and decreased interleukin-6 and tumor necrosis factor-a release both in vitro and in vivo (33) .
Increased LDH and aspartate transaminase (AST) activity are considered as nonspecific markers of cardiac injury as well as markers of increased metabolic activity (34) . Reduction in LDH and AST activity therefore suggests decreased metabolic activity and cardioprotection in OLE-supplemented rats. Additionally, OLE supplementation increased plasma urea concentration. High-fat diet feeding decreased urea synthesis in rats (35, 36) due to reduced activities of all the enzymes of the urea cycle (35) . These results along with improved glucose metabolism indicate that OLE attenuated the diet-induced metabolic deterioration. OLE supplementation also reduced plasma concentrations of uric acid, also one of the major endogenous water-soluble antioxidants (37) , and malondialdehyde, a marker of lipid peroxidation (38) .
Our finding of increased LV internal diameter in diastole and increased relative wall thickness in the LV is consistent with subtle eccentric LV hypertrophy (39) induced by HCHF feeding. The fact that OLE supplementation did not attenuate any echocardiography variables or reduce blood pressure suggests that the LV hypertrophy may have been produced in response to systemic hypertension caused by HCHF feeding (39) . However, previous studies have ascertained the direct relationship between increased superoxide production, diastolic stiffness, and cardiac fibrosis (25, 40) . Consistent with these observations, OLE supplementation decreased LV diastolic stiffness and fibrosis compared with the HCHF rats. Additionally, OLE supplementation reduced infiltration by inflammatory cells into the LV. Although the antioxidant and free radical scavenging properties of olive leaf and its constituents have been previously described (41) , this is the first study to our knowledge that demonstrates the role of olive leaf-derived polyphenols in preventing inflammation and oxidative damage-induced primary myocardial insult.
OLE supplementation also caused marked improvement in vascular function. OLE-supplemented rats had enhanced vascular relaxant responses to acetylcholine and sodium nitroprusside in the aortic rings derived from the treated rats. Other ex vivo studies have demonstrated the vasodilative effect of oleuropein on isolated rat aorta (42) , attributed to L-type Ca 2+ channel antagonistic effects (43) . Our data therefore suggest that in vivo, OLE supplementation protected the aorta against the free radical-induced impairment of the NO · -mediated relaxation, thereby preserving the role of vascular endothelium in vasodilation.
Limited data are available on the effects of olive leaf or its major constituents on the liver. To date, our study is the first to our knowledge to investigate the hepatoprotective effects of OLE in vivo. The reduced liver weight in OLE-supplemented rats is probably due to reduced portal collagen deposition and fat deposition in the liver. Nonalcoholic fatty liver disease is recognized as the hepatic manifestation of the metabolic syndrome (44) . Nonalcoholic fatty liver disease can be categorized as simple steatosis and nonalcoholic steatohepatitis (NASH) (44) . NASH is proposed as a fatty liver disease associated with diffuse fatty infiltration, inflammation, pericellular fibrosis, and extremely elevated transaminase activity (44, 45) . We clearly show that OLE improved the pathological features of NASH in the HCHF rats.
The results of this study demonstrate that treatment of dietinduced metabolic syndrome in rats with OLE attenuated the metabolic, as well as structural and functional, changes in the heart and liver without decreasing blood pressure. We propose that OLE decreased cardiac and hepatic injury through the antioxidant and antiinflammatory effects of polyphenols, mainly oleuropein and hydroxytyrosol.
